Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1953 1
1958 1
1988 1
2009 1
2010 4
2012 2
2013 1
2014 1
2016 4
2017 11
2018 6
2019 11
2020 11
2021 5
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y, Sun XS, Pointreau Y, Le Tourneau C, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Calderon B, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Damstrup L, Crompton P, Ennaji A, Gollmer K, Nauwelaerts H, Bourhis J. Tao Y, et al. Among authors: bera g. Eur J Cancer. 2023 Apr;183:24-37. doi: 10.1016/j.ejca.2022.12.015. Epub 2023 Jan 9. Eur J Cancer. 2023. PMID: 36796234 Free article. Clinical Trial.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J. Sun XS, et al. Among authors: bera g. Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3. Lancet Oncol. 2020. PMID: 32758455 Clinical Trial.
Novel PET tracers: added value for endocrine disorders.
Bergeret S, Charbit J, Ansquer C, Bera G, Chanson P, Lussey-Lepoutre C. Bergeret S, et al. Among authors: bera g. Endocrine. 2019 Apr;64(1):14-30. doi: 10.1007/s12020-019-01895-z. Epub 2019 Mar 14. Endocrine. 2019. PMID: 30875057 Review.
[Esophageal cancer].
Dupuis O, Ganem G, Béra G, Pointreau Y, Pradier O, Martin P, Mirabel X, Denis F. Dupuis O, et al. Among authors: bera g. Cancer Radiother. 2010 Nov;14 Suppl 1:S74-83. doi: 10.1016/S1278-3218(10)70010-X. Cancer Radiother. 2010. PMID: 21129673 French.
Biological response to dissolved versus dispersed oil.
Bera G, Doyle S, Passow U, Kamalanathan M, Wade TL, Sylvan JB, Sericano JL, Gold G, Quigg A, Knap AH. Bera G, et al. Mar Pollut Bull. 2020 Jan;150:110713. doi: 10.1016/j.marpolbul.2019.110713. Epub 2019 Nov 20. Mar Pollut Bull. 2020. PMID: 31757392
Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Rogé M, Pointreau Y, Sargos P, Meyer E, Schick U, Hasbini A, Rio E, Bera G, Ruffier A, Quivrin M, Chasseray M, Latorzeff I, Martin E, Guimas V, Pommier P, Leroy T, Ronchin P, Lepinoy A, Grand A, Cartier L, Didas O, Denis F, Libois V, Blanc-Lapierre A, Supiot S. Rogé M, et al. Among authors: bera g. Clin Transl Radiat Oncol. 2023 Mar 8;40:100613. doi: 10.1016/j.ctro.2023.100613. eCollection 2023 May. Clin Transl Radiat Oncol. 2023. PMID: 36968576 Free PMC article.
62 results